US Stock Market Update: Longevity Health up 9.79%

U.S. Stock Market Midday Update Changqing Technology rose 9.79%, with increased trading volume. Based on recent important news: On August 11, the Hang Seng Pharmaceutical ETF rose, with a broad market outlook for weight loss drugs, driving up the stock prices of related companies. On August 12, Zhonghui Biotechnology's stock price increased on its second day of listing, with heightened market attention on innovative pharmaceutical companies. On August 15, Dongfang Caifu's trading volume reached 40 billion yuan, currently up 9%, indicating increased market activity. Stocks with High Trading Volume in the Industry AbbVie rose 0.65%, with increased trading volume. Based on recent important news: On August 13, AbbVie announced its second-quarter results, with revenue growth of 6.6% year-on-year, exceeding market expectations, and adjusted earnings per share above expectations, leading to an upward revision of full-year profit forecasts, with the stock price rising 0.65%. On August 12, AbbVie announced a $195 million investment to expand its active pharmaceutical ingredient manufacturing in the U.S., boosting market confidence. On August 15, Point72 Hong Kong Ltd. increased its holdings in AbbVie, showing investor confidence in its future growth. Precigen rose 59.19%, with a trading volume of $488 million. Based on recent important news: On August 15, Precigen announced that its drug Papzimeos received full FDA approval for the treatment of recurrent respiratory papillomatosis. This approval makes it the only treatment option for the disease, driving the stock price up 82.2%. On August 15, HC Wainwright & Co. raised Precigen's target price from $6 to $8.5, further boosting market confidence. On August 15, Precigen began promoting Papzimeos, with the market holding an optimistic outlook on its sales prospects, leading to a 44.32% increase in the stock price during pre-market trading. Regeneron Pharmaceuticals rose 2.42%, with increased trading volume. Based on recent important news: On August 13, Regeneron Pharmaceuticals announced its second-quarter results for 2025, with revenue growth to $3.676 billion, driving the stock price up 2.42%. On August 14, analysts maintained a "moderate buy" rating on Regeneron Pharmaceuticals but did not include it in the top recommendations, having limited impact. On August 15, market attention on Regeneron Pharmaceuticals increased, with significantly expanded trading volume. Stocks with High Market Capitalization in the Industry Amgen rose 1.80%, with increased trading volume. Based on recent key news: On August 13, Amgen announced its second-quarter results, with revenue growth of 9% year-on-year and net profit growth of 92% year-on-year, exceeding market expectations, leading to a rise in stock price. On August 14, White House advisor Navarro claimed that pharmaceutical tariffs might be introduced, causing Amgen's stock price to rise by 0.6% On August 16, Envision Research upgraded Amgen's rating from Hold to Buy, believing it has a greater advantage under drug pricing pressure